Fortress Biotech, Inc. (FBIO)
2.72
+0.01
(+0.37%)
USD |
NASDAQ |
Sep 04, 16:00
2.67
-0.05
(-1.84%)
After-Hours: 20:00
Fortress Biotech Research and Development Expense (Quarterly) : 0.805M for June 30, 2026
Research and Development Expense (Quarterly) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Research and Development Expense (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2026 | 0.805M |
| March 31, 2026 | 0.54M |
| December 31, 2025 | -0.367M |
| September 30, 2025 | 0.208M |
| June 30, 2025 | 8.126M |
| March 31, 2025 | 3.938M |
| December 31, 2024 | 9.94M |
| September 30, 2024 | 9.446M |
| June 30, 2024 | 12.67M |
| March 31, 2024 | 24.84M |
| December 31, 2023 | 14.08M |
| September 30, 2023 | 20.35M |
| June 30, 2023 | 32.14M |
| March 31, 2023 | 39.51M |
| December 31, 2022 | 35.12M |
| September 30, 2022 | 29.90M |
| June 30, 2022 | 33.13M |
| March 31, 2022 | 36.72M |
| December 31, 2021 | 43.05M |
| September 30, 2021 | 28.08M |
| June 30, 2021 | 33.83M |
| March 31, 2021 | 20.15M |
| December 31, 2020 | 17.96M |
| September 30, 2020 | 13.76M |
| June 30, 2020 | 17.27M |
| Date | Value |
|---|---|
| March 31, 2020 | 15.12M |
| December 31, 2019 | 23.62M |
| September 30, 2019 | 15.27M |
| June 30, 2019 | 18.71M |
| March 31, 2019 | 23.72M |
| September 30, 2018 | 19.79M |
| June 30, 2018 | 17.49M |
| March 31, 2018 | 25.06M |
| December 31, 2017 | 14.41M |
| September 30, 2017 | 16.19M |
| June 30, 2017 | 13.48M |
| March 31, 2017 | 8.404M |
| December 31, 2016 | 10.58M |
| September 30, 2016 | 8.316M |
| June 30, 2016 | 8.407M |
| March 31, 2016 | 7.819M |
| December 31, 2015 | 5.756M |
| September 30, 2015 | 10.97M |
| June 30, 2015 | 3.959M |
| March 31, 2015 | 9.081M |
| December 31, 2014 | 1.766M |
| September 30, 2014 | 1.609M |
| June 30, 2014 | 2.445M |
| March 31, 2014 | 3.452M |
| December 31, 2013 | 6.552M |
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Research and Development Expense (Quarterly) Benchmarks
| Inovio Pharmaceuticals, Inc. | 10.50M |
| Ironwood Pharmaceuticals, Inc. | 21.96M |
| Kura Oncology, Inc. | 61.89M |
| Spero Therapeutics, Inc. | 3.434M |
| Cue Biopharma, Inc. | 48.98M |